Sargent Investment Group LLC Lowers Stock Position in Matinas Biopharma Holdings, Inc. (NYSE:MTNB)

Sargent Investment Group LLC trimmed its position in shares of Matinas Biopharma Holdings, Inc. (NYSE:MTNB) by 97.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 80,240 shares of the company’s stock after selling 3,411,760 shares during the quarter. Sargent Investment Group LLC’s holdings in Matinas Biopharma were worth $284,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Alliance Wealth Management Group purchased a new position in Matinas Biopharma in the 2nd quarter worth approximately $299,000. Towercrest Capital Management purchased a new position in Matinas Biopharma in the second quarter worth approximately $299,000. Finally, Highbridge Capital Management LLC purchased a new stake in Matinas Biopharma in the second quarter valued at approximately $1,685,000. 11.77% of the stock is owned by institutional investors.

Matinas Biopharma Stock Down 5.6 %

MTNB stock traded down $0.04 during trading on Thursday, hitting $0.67. 595,899 shares of the stock traded hands, compared to its average volume of 78,146. Matinas Biopharma Holdings, Inc. has a one year low of $0.50 and a one year high of $21.50. The company has a market capitalization of $3.36 million, a P/E ratio of -0.13 and a beta of 1.73.

Matinas Biopharma (NYSE:MTNB) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02).

Analyst Upgrades and Downgrades

Several analysts have recently commented on MTNB shares. Maxim Group reiterated a “hold” rating on shares of Matinas Biopharma in a research report on Thursday, October 31st. Alliance Global Partners cut shares of Matinas Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 1st.

About Matinas Biopharma

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.